Immix Biopharma Completes NEXICART-2 Enrollment for NXC-201

Immix Biopharma ( (IMMX) ) has shared an announcement.

On March 30, 2026, Immix Biopharma announced it had completed enrollment in its 40-patient NEXICART-2 Phase 2 trial of NXC-201 for relapsed or refractory AL amyloidosis, keeping to prior guidance and setting up topline data readout expected in the third quarter of 2026. The study is designed with registrational intent in the U.S., and the company views NXC-201 as a potentially transformative, one-time CAR-T treatment that could address a rapidly growing, high-mortality disease with no approved therapies in this specific setting.

Management framed NEXICART-2 as a biologics license application-enabling trial, indicating that positive results could support a BLA and pave the way for a planned commercial launch of NXC-201 in AL amyloidosis. To bolster its regulatory and launch readiness, Immix Biopharma also appointed hematologist-oncologist Richard Graydon, formerly of Merck and Johnson & Johnson and experienced in multiple successful drug and biologic submissions, as chief medical officer, signaling a push to convert its clinical and regulatory momentum into a commercial foothold in the amyloidosis market.

The most recent analyst rating on (IMMX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Immix Biopharma stock, see the IMMX Stock Forecast page.

More about Immix Biopharma

Immix Biopharma, Inc. is a Nasdaq-listed biotechnology company focused on developing cell therapies for relapsed and refractory AL amyloidosis, a rare and often fatal disease in which misfolded light-chain proteins damage vital organs. Its lead product candidate is NXC-201, a sterically optimized BCMA-targeted CAR-T therapy that has received Breakthrough Therapy, RMAT and Orphan Drug designations in the U.S. and EU, and is being evaluated in the NEXICART-2 Phase 2 trial with a registrational design.

The company positions itself as a global leader in this niche hematologic indication, targeting a U.S. patient population projected to reach about 38,500 by 2026, against the backdrop of an amyloidosis market forecast to expand from $3.6 billion in 2017 to $6 billion by 2025. This focus on a growing, underserved segment, combined with regulatory incentives, underpins Immix Biopharma’s strategy to commercialize NXC-201 as a potentially first-in-class therapy for patients who have exhausted existing treatment options.

Average Trading Volume: 886,610

Technical Sentiment Signal: Buy

Current Market Cap: $431.7M

For detailed information about IMMX stock, go to TipRanks’ Stock Analysis page.